Cargando…

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

PURPOSE: This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) treated in the phase 3 QuANTUM-R study (NCT02039726)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Dongwoo, Ludwig, Elizabeth, Jaworowicz, David, Huang, Hannah, Fiedler-Kelly, Jill, Cortes, Jorge, Ganguly, Siddhartha, Khaled, Samer, Krämer, Alwin, Levis, Mark, Martinelli, Giovanni, Perl, Alexander, Russell, Nigel, Abutarif, Malaz, Choi, Youngsook, Yin, Ophelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946665/ https://www.ncbi.nlm.nih.gov/pubmed/33415416 http://dx.doi.org/10.1007/s00280-020-04204-y

Ejemplares similares

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

Effect of Food on the Pharmacokinetics of Quizartinib
por: Li, Jianke, et al.
Publicado: (2020)

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
por: Schaab, C, et al.
Publicado: (2014)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Quizartinib (AC220): a promising option for acute myeloid leukemia
por: Zhou, Fang, et al.
Publicado: (2019)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2017)

Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six‐Minute Walk Test
por: Hamuro, Lora, et al.
Publicado: (2017)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2021)

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
por: Zorn, Julie A., et al.
Publicado: (2015)

Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
por: Ouchida, Amanda Tomie, et al.
Publicado: (2018)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
por: Patel, Ami B., et al.
Publicado: (2020)

Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
por: Fletcher, Luke, et al.
Publicado: (2020)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020)

A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics
por: Li, Jianke, et al.
Publicado: (2019)

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
por: Yin, Ophelia, et al.
Publicado: (2021)

The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
por: Lee, Ye Seung, et al.
Publicado: (2015)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
por: Tormo, Mar, et al.
Publicado: (2023)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
por: Ruehs, Hauke, et al.
Publicado: (2023)

Implications of Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes
por: Malik, Marek, et al.
Publicado: (2018)

Paroxetine‐induced QTc prolongation
por: Otsuka, Yuji
Publicado: (2017)

Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors
por: Lu, Yasong, et al.
Publicado: (2022)

Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?
por: Gupta, Anunay, et al.
Publicado: (2020)

Correction to: Implications of Individual QT/RR Profiles—Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes
por: Malik, Marek, et al.
Publicado: (2019)

The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions
por: Bhullar, Jasjeet, et al.
Publicado: (2013)

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
por: Papadopoulos, Kyriakos P., et al.
Publicado: (2018)

Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite
por: Li, Jianke, et al.
Publicado: (2019)

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
por: Hong, Ying, et al.
Publicado: (2021)

Lightweight user authentication scheme for roaming service in GLOMONET with privacy preserving
por: Kang, Dongwoo, et al.
Publicado: (2021)

Is the widening of the QTc associated with mortality in sepsis?
por: Nogueira, AC, et al.
Publicado: (2007)

Ketamine-induced QTc interval prolongation
por: Singh, Tejinder S. Swaran, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vd6tltrc8tbducir7nd3hqq4v1